Patents Assigned to CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD
  • Patent number: 10751371
    Abstract: Provided are uses of allogeneic interstitial vessel-layer cells and allogeneic mesenchymal progenitor cells in the preparation of a pharmaceutical composition for preventing or treating osteoarthritis (OA). Also provided is a pharmaceutical composition containing the allogeneic interstitial vessel-layer cells and the allogeneic mesenchymal progenitor cells.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: August 25, 2020
    Assignees: Cellular Biomedicine Group (Shanghai) Ltd., Cellular Biomedicine Group (Wuxi) Ltd.
    Inventors: Wei Cao, Xiaoling Zeng, Mohammad Abdul Kaium, Yujie Zhou
  • Publication number: 20200170242
    Abstract: The present invention relates to the preparation and use of a cell cryopreservation formulation convenient for clinical use. In particular, provided is a cell cryopreservation (freezing) formulation, comprising: (1) a cell; (2) a cryopreservation diluent; the cryopreservation diluent comprising: an aqueous solution of sodium chloride, protective proteins, and dimethyl sulfoxide. The invention also relates to a corresponding cell resuscitation method. The invention adopts a no-wash cryopreservation solution for preparation of a cell frozen preparation, and the cell resuscitation and dilution for clinical use can be carried out by a simple formulating operation.
    Type: Application
    Filed: May 24, 2018
    Publication date: June 4, 2020
    Applicants: CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD., CELLULAR BIOMEDICINE GROUP (WUXI) LTD.
    Inventors: Li ZHANG, Fei WANG, Jiaping HE, Nanjing LIN, Liping LIU, Xin LIU, Chao LI, Shuqian YU, Yonglai HU, Jiawei ZHAO, Zhe SUN, Xiaoyu LU
  • Publication number: 20200002400
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Application
    Filed: February 8, 2018
    Publication date: January 2, 2020
    Applicants: CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD., CELLULAR BIOMEDICINE GROUP (WUXI) LTD.
    Inventors: Yihong YAO, Jiaqi HUANG, Shigui ZHU, Wei ZHU, Xin YAO, Zhiyuan LI, Li ZHANG, Lin ZHU, Anyun MA, Yutian WEI, Yanfeng LI, Qingxia WANG, Jiaping HE
  • Patent number: 9956250
    Abstract: Provided are uses of allogeneic interstitial vessel-layer cells and allogeneic mesenchymal progenitor cells in the preparation of a pharmaceutical composition for preventing or treating osteoarthritis (OA). Also provided is a pharmaceutical composition containing the allogeneic interstitial vessel-layer cells and the allogeneic mesenchymal progenitor cells.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: May 1, 2018
    Assignees: Cellular Biomedicine Group (Shanghai) Ltd, Cellular Biomedicine Group (Wuxi) Ltd.
    Inventors: Wei Cao, Xiaoling Zeng, Mohammad Abdul Kaium, Yujie Zhou
  • Patent number: 9481865
    Abstract: Disclosed is a serum-free freezing medium used in adipose-derived stem cells and a method for establishing an adipose-derived stem cell library. The serum-free freezing medium comprises a serum-free culture medium, dimethyl sulfoxide and a serum substitution component KSR; the defects of unstable freezing quality of the adipose-derived stem cells and influence of harmful factors in serum on the adipose-derived stem cells are solved, and the adipose-derived stem cells stored have the advantages of high survival percentage, well adherence growth and strong differentiation capacity.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: November 1, 2016
    Assignees: Cellular Biomedicine Group (Shanghai) Ltd, Cellular Biomedicine Group (Wuxi) Ltd
    Inventors: Helen Zhang, Luyi Zhang, Wei Cao
  • Publication number: 20150011429
    Abstract: Disclosed is a serum-free freezing medium used in adipose-derived stem cells and a method for establishing an adipose-derived stem cell library. The serum-free freezing medium comprises a serum-free culture medium, dimethyl sulfoxide and a serum substitution component KSR; the defects of unstable freezing quality of the adipose-derived stem cells and influence of harmful factors in serum on the adipose-derived stem cells are solved, and the adipose-derived stem cells stored have the advantages of high survival percentage, well adherence growth and strong differentiation capacity.
    Type: Application
    Filed: August 6, 2012
    Publication date: January 8, 2015
    Applicants: CELLULAR BIOMEDICINE GROUP (WUXI) LTD, CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD
    Inventors: Helen Zhang, Luyi Zhang, Wei Cao